Related Experiment Videos
Improved survival for childhood acute lymphoblastic leukemia: possible effect of protocol compliance
O B Eden1, C A Stiller, M P Gerrard
1Department of Paediatric Haematology, Royal Hospital for Sick Children, Edinburgh, United Kingdom.
Insights
High compliance with treatment protocols significantly improved survival rates for childhood acute lymphoblastic leukemia (ALL). This study highlights the importance of adherence in achieving better outcomes for pediatric cancer patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trials
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Treatment protocols aim to maximize survival rates, but variations in compliance can impact outcomes.
Purpose of the Study:
- To analyze survival rates in a cohort of pediatric ALL patients treated between 1970-1981.
- To compare these outcomes with national averages and investigate the impact of treatment compliance.
Main Methods:
- Retrospective analysis of 77 pediatric ALL cases treated at a single hospital.
- Treatment followed Medical Research Council (MRC) UKALL protocols I-VII with emphasis on compliance.
Main Results:
- The 5-year overall survival rate was 64%, significantly higher than the national average of 47%.
- Survival was particularly improved for children aged 2-9 years (76% vs. 50%) and those with white blood cell counts under 10 x 10(9)/L (87% vs. 57%).
- Achieved survival rates for these subgroups approached those of the UKALL VIII trial, suggesting the benefits of sustained treatment and protocol adherence.
Conclusions:
- Rigorous adherence to treatment protocols can substantially improve survival rates in pediatric acute lymphoblastic leukemia.
- Improved outcomes for good-prognosis patients may be linked to enhanced doctor compliance with protocols.
- Sustained treatment duration appears crucial for improving outcomes in poor-prognosis patients.
Abstract:
Survival rates were analyzed for an effectively population-based series of 77 children with acute lymphoblastic leukemia treated at one hospital during 1970-1981. Treatment was according to Medical Research Council protocols UKALL I to UKALL VII but with a great emphasis on compliance. The relapse-free survival rate was 54.5% at 5 years. The overall 5-year survival rate of 64% was substantially higher than the 47% recorded during a similar period over the rest of Britain. The difference between survival rates in this series and nationally was especially marked for children aged 2-9 years (76% versus 50%) and with white blood count under 10 x 10(9)/L (87% versus 57%). For both of these groups, the survival rates achieved were similar to those now being recorded for the UKALL VIII trial in which treatment is more sustained than in its predecessors and there is greater emphasis on doctor compliance with protocol. These results suggest that although the advantage of UKALL VIII over previous trials for poor prognosis patients may be attributed to the more sustained treatment, the improvement for good prognosis patients may be due to more rigorous compliance with protocol.